Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.
Sweet syndrome following sars-cov2 vaccination / Baffa M.E.; Maglie R.; Giovannozzi N.; Montefusco F.; Senatore S.; Massi D.; Antiga E.. - In: VACCINES. - ISSN 2076-393X. - ELETTRONICO. - 9:(2021), pp. 0-0. [10.3390/vaccines9111212]
Sweet syndrome following sars-cov2 vaccination
Baffa M. E.;Maglie R.;Giovannozzi N.;Montefusco F.;Senatore S.;Massi D.;Antiga E.
2021
Abstract
Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
